Last reviewed · How we verify
PHMB 0.08%
PHMB is an antimicrobial agent that works by disrupting the cell membrane of microorganisms.
PHMB is an antimicrobial agent that works by disrupting the cell membrane of microorganisms. Used for Treatment of blepharitis.
At a glance
| Generic name | PHMB 0.08% |
|---|---|
| Also known as | Polihexanide 0.8 mg/ml |
| Sponsor | SIFI SpA |
| Drug class | Antimicrobial |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
PHMB is a quaternary ammonium compound that has been shown to exhibit broad-spectrum antimicrobial activity against bacteria, viruses, and fungi. It is thought to exert its effects by interacting with the cell membrane of microorganisms, ultimately leading to cell lysis and death.
Approved indications
- Treatment of blepharitis
Common side effects
- Skin irritation
Key clinical trials
- Retrospective Chart Review of Patients With Acanthamoeba Keratitis Who Have Received 0.8 mg/mL Polihexanide as Part of the "Medicines in Special Situations" (Medicamentos en Situaciones Especiales) Program in Spain.
- Polihexanide (PHMB) Eye Drops in Patients Affected by Acanthamoeba Keratitis (PHASE3)
- Safety and Tolerability of Preservative-free Polyhexamethylene Biguanide (PHMB) Ophthalmic Solution in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PHMB 0.08% CI brief — competitive landscape report
- PHMB 0.08% updates RSS · CI watch RSS
- SIFI SpA portfolio CI